Zydus Lifesciences launches Mirabegron Extended-Release Tablets in US market
Zydus Lifesciences Limited has announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the US market, following the final approval from the United States ... Read More
Urovant Sciences acquires licensing for hMaxi-K gene therapy to treat overactive bladder from Ion Channel
Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a promising gene therapy, hMaxi-K. This therapy is ... Read More